Dividend
-
-
-
-
-
-
-
Cyprium Therapeutics sells rare disease priority review voucher for $205 million
-
-
-
-
-
-
-
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
-
-
-
-
-
-
-
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
-
-
-
-
-
-
-
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
-
-
-
-
-
-
-
Fortress Biotech (FBIO) Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination
-
-
-
-
-
-
-
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
-
450,968 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

